Publications by authors named "B Joy Snider"
Orally bioavailable, synthetic nonpeptide agonists (NPAs) of the glucagon-like peptide-1 receptor (GLP-1R) may offer an effective, scalable pharmacotherapy to address the metabolic disease epidemic. One of the first molecules in the emerging class of GLP-1R NPAs is orforglipron, which is in clinical development for treating type 2 diabetes and obesity. Here, we characterized the pharmacological properties of orforglipron in comparison with peptide-based GLP-1R agonists and other NPAs.
View Article and Find Full Text PDFContext: Breast and cervical cancer are among the most common types of cancer, with breast cancer being a leading cause of death in females. Participation in preventive cancer screening is thought to be lower for females with spinal cord injury (SCI) compared to the general population, which could lead to late diagnosis and increased mortality.
Objective: To summarize evidence on the prevalence of breast and cervical cancer, adherence to cancer screening recommendations, and factors influencing participation in preventive programs among females with SCI.
Article Synopsis
- The Knight-Alzheimer Disease Research Center at Washington University has been at the forefront of Alzheimer disease research for over 40 years, significantly enhancing our understanding through various studies on cognitive and molecular aspects.
- Over 26,000 biological samples have been collected from participants, including DNA, RNA, plasma, and cerebrospinal fluid, to support extensive research on dementia and aging.
- The Genetics and High Throughput -Omics core has conducted in-depth molecular profiling to discover new risk factors, biomarkers, and potential treatment targets for Alzheimer disease.
Objectives: Evaluate if nonoperative or operative treatment of displaced clavicle fractures delivers reduced rates of nonunion and improved Disability of the Arm, Shoulder, and Hand (DASH) scores.
Design: Multicenter, prospective, observational.
Setting: Seven Level 1 Trauma Centers in the United States.
Background: Clinical trial satisfaction is increasingly important for future trial designs and is associated with treatment adherence and willingness to enroll in future research studies or to recommend trial participation. In this post-trial survey, we examined participant satisfaction and attitudes toward future clinical trials in the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU).
Methods: We developed an anonymous, participant satisfaction survey tailored to participants enrolled in the DIAN-TU-001 double-blind clinical trial of solanezumab or gantenerumab and requested that all study sites share the survey with their trial participants.